A new bismuth-based CT agent was synthesized through a facile synthesis strategy. The in vitro stability, toxicity and CT performance were evaluated. The in vivo imaging performance was investigated using three different doses (0.5, 1.2 and 5 mmol/kg) and the result obtained at 1.2 mmol/kg was compared with the clinically approved CT agent iopamidol at the same dosage.
Bi-HPDO3A as a novel contrast agent for X-ray computed tomography
Rizzo, Rebecca;Capozza, Martina;Carrera, Carla;Terreno, Enzo
2023-01-01
Abstract
A new bismuth-based CT agent was synthesized through a facile synthesis strategy. The in vitro stability, toxicity and CT performance were evaluated. The in vivo imaging performance was investigated using three different doses (0.5, 1.2 and 5 mmol/kg) and the result obtained at 1.2 mmol/kg was compared with the clinically approved CT agent iopamidol at the same dosage.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Bi-HPDO3A_2023.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
3 MB
Formato
Adobe PDF
|
3 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
